These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9510443)

  • 1. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably.
    Lindgren AC; Hagenäs L; Müller J; Blichfeldt S; Rosenborg M; Brismar T; Ritzén EM
    Acta Paediatr; 1998 Jan; 87(1):28-31. PubMed ID: 9510443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
    Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
    J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome.
    Angulo M; Castro-Magana M; Mazur B; Canas JA; Vitollo PM; Sarrantonio M
    J Pediatr Endocrinol Metab; 1996; 9(3):393-400. PubMed ID: 8887149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose growth hormone treatment in infants and toddlers with Prader-Willi syndrome is comparable to higher dosage regimens.
    Scheermeyer E; Harris M; Hughes I; Crock PA; Ambler G; Verge CF; Bergman P; Werther G; Craig ME; Choong CS; Davies PSW;
    Growth Horm IGF Res; 2017 Jun; 34():1-7. PubMed ID: 28427039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The behavioral impact of growth hormone treatment for children and adolescents with Prader-Willi syndrome: a 2-year, controlled study.
    Whitman BY; Myers S; Carrel A; Allen D
    Pediatrics; 2002 Feb; 109(2):E35. PubMed ID: 11826245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent.
    Carrel AL; Myers SE; Whitman BY; Allen DB
    J Pediatr Endocrinol Metab; 2001; 14(8):1097-105. PubMed ID: 11592566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of growth hormone treatment in children with Prader-Willi syndrome over a 30-year period: a single tertiary center experience.
    Gamage DS; Ambler G; Chan A; Srinivasan S; Maguire AM; Cho YH
    J Pediatr Endocrinol Metab; 2024 Aug; 37(8):680-685. PubMed ID: 39089289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group.
    Lindgren AC; Ritzén EM
    Acta Paediatr Suppl; 1999 Dec; 88(433):109-11. PubMed ID: 10626558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study.
    Corripio R; Tubau C; Calvo L; Brun C; Capdevila N; Larramona H; Gabau E
    J Pediatr Endocrinol Metab; 2019 Aug; 32(8):879-884. PubMed ID: 31271556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulated GH levels during the transition phase in Prader-Willi syndrome.
    Grugni G; Marzullo P; Delvecchio M; Iughetti L; Licenziati MR; Osimani S; Ragusa L; Salvatoni A; Sartorio A; Stagi S; Crinò A;
    J Endocrinol Invest; 2021 Jul; 44(7):1465-1474. PubMed ID: 33095904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome.
    Grugni G; Crinò A; Pagani S; Meazza C; Buzi F; De Toni T; Gargantini L; Pilotta A; Pozzan GB; Radetti G; Ragusa L; Salvatoni A; Sartorio A; Bozzola M;
    J Pediatr Endocrinol Metab; 2011; 24(7-8):477-81. PubMed ID: 21932585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.
    Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Christiansen JS; Höybye C
    Endocrine; 2012 Apr; 41(2):191-9. PubMed ID: 22081257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in carbohydrate metabolism and insulin resistance in patients with Prader-Willi Syndrome (PWS) under growth hormone therapy].
    Lämmer C; Weimann E
    Wien Med Wochenschr; 2007 Feb; 157(3-4):82-8. PubMed ID: 17340066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin homeostasis. Swedish National Growth Hormone Advisory Group.
    Lindgren AC; Hagenäs L; Ritzén EM
    Horm Res; 1999; 51(4):157-61. PubMed ID: 10474015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome.
    Höybye C; Hilding A; Jacobsson H; Thorén M
    Clin Endocrinol (Oxf); 2003 May; 58(5):653-61. PubMed ID: 12699450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial.
    Bakker NE; Siemensma EP; Koopman C; Hokken-Koelega AC
    Horm Res Paediatr; 2015; 83(5):321-31. PubMed ID: 25764996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
    Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Schroor EJ; Van Alfen AA; Van Leeuwen M; Van Pinxteren-Nagler E; Van Wieringen H; Vreuls RC; Zwaveling-Soonawala N; de Ridder MA; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4013-22. PubMed ID: 24001750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone improves body composition and motor development in infants with Prader-Willi syndrome after six months.
    Whitman B; Carrel A; Bekx T; Weber C; Allen D; Myers S
    J Pediatr Endocrinol Metab; 2004 Apr; 17(4):591-600. PubMed ID: 15198290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.